Results 31 to 40 of about 693,546 (355)

Clinical determinants of primary and secondary fatigue in patients with Parkinson’s disease [PDF]

Journal of Neurology, 2013
Clinical and psychosocial factors associated separately with primary and secondary fatigue in Parkinson's disease (PD) patients have not been thoroughly studied before. The aim of our study was to assess factors associated with different fatigue domains in groups with primary and secondary fatigue in PD separately.
Skorvanek, Matej, Nagyova, Iveta, Rosenberger, Jaroslav, Krokavcova, Martina, Saeedian, Radka Ghorbani, Groothoff, Johan W., Gdovinova, Zuzana, van Dijk, Jitse P.   +7 more
openaire   +2 more sources

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. [PDF]

, 2019
The gold standard for a definitive diagnosis of Parkinson disease (PD) is the pathologic finding of aggregated α-synuclein into Lewy bodies and for Alzheimer disease (AD) aggregated amyloid into plaques and hyperphosphorylated tau into tangles.
Brundin, P, Cambi, F, Espay, AJ, Fasano, A, Fernandez, HH, Gan-Or, Z, Greenamyre, JT, Josephs, KA, Kauffman, MA, Lang, AE, Leverenz, JB, Litvan, I, Marsili, L, Mata, IF, Merola, A, Morgante, F, Perry, G, Sardi, SP, Savica, R, Schwarzschild, MA, Sherer, T, Simon, DK, Standaert, DG, Tanner, CM, Vizcarra, JA, Yamasaki, TR, Zabetian, CP   +26 more
core   +3 more sources

Utilising telehealth to support exercise and physical activity in people with Parkinson disease: a program evaluation using mixed methods

BMC Health Services Research, 2023
Background Physical activity and exercise play a key role in managing Parkinson disease. This study aimed to: 1) determine if physiotherapy supported by telehealth helped people with Parkinson disease (PwP) to adhere to a home-based exercise program and ...
Allyson Flynn, Elisabeth Preston, Sarah Dennis, Colleen G. Canning, Natalie E. Allen   +4 more
doaj   +1 more source

Trial of Deferiprone in Parkinson's Disease.

New England Journal of Medicine, 2022
BACKGROUND Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder.
D. Devos, J. Labreuche, O. Rascol, J. Corvol, A. Duhamel, Pauline Guyon Delannoy, W. Poewe, Y. Compta, N. Pavese, E. Růžička, P. Dušek, B. Post, B. Bloem, D. Berg, W. Maetzler, Markus Otto, M. Habert, S. Lehéricy, J. Ferreira, R. Dodel, C. Tranchant, A. Eusebio, S. Thobois, A. Marques, W. Meissner, F. Ory-Magne, U. Walter, R. D. de Bie, Miguel Gago, D. Vilas, J. Kulisevsky, C. Januário, M. Coelho, S. Behnke, P. Worth, K. Seppi, T. Ouk, Camille Potey, C. Leclercq, R. Viard, Grégory Kuchcinski, Renaud Lopes, J. Pruvo, P. Pigny, G. Garçon, O. Simonin, Jesse A. Carpentier, Anne-Sophie Rolland, D. Nyholm, C. Scherfler, J. F. Mangin, M. Chupin, R. Bordet, D. Dexter, C. Fradette, M. Spino, F. Tricta, S. Ayton, A. Bush, J. Devedjian, J. Duce, I. Cabantchik, L. Defebvre, D. Deplanque, C. Moreau   +64 more
semanticscholar   +1 more source

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial

JAMA Neurology, 2019
Importance Exenatide, a glucagon-like peptide 1 agonist used in type 2 diabetes, was recently found to have beneficial effects on motor function in a randomized, placebo-controlled trial in Parkinson disease (PD).
D. Athauda, S. Gulyani, H. K. Karnati, Yazhou Li, D. Tweedie, M. Mustapić, Sahil Chawla, Kashfia Chowdhury, Simon S. Skene, N. Greig, D. Kapogiannis, T. Foltynie   +11 more
semanticscholar   +1 more source

Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches

Cells, 2022
Following Alzheimer’s, Parkinson’s disease (PD) is the second-most common neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile, and massive social costs worldwide.
M. Vidović, Milena Rikalovic
semanticscholar   +1 more source

Mechanisms of peripheral levodopa resistance in Parkinson’s disease

npj Parkinson's Disease, 2022
Parkinson’s disease (PD) is an increasingly common neurodegenerative condition. The disease has a significant negative impact on quality of life, but a personalized management approach can help reduce disability. Pharmacotherapy with levodopa remains the
Milan Beckers, B. Bloem, M. Verbeek
semanticscholar   +1 more source

Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial

EBioMedicine, 2022
Summary: Background: Synucleinopathies such as Parkinson ́s disease (PD), Dementia with Lewy bodies (DLB) and Multiple System Atrophy (MSA) are characterized by deposition of misfolded and aggregated α-synuclein.
Johannes Levin, Nand Sing, Sue Melbourne, Amber Morgan, Carla Mariner, Maria Grazia Spillantini, Michal Wegrzynowicz, Jeffrey W. Dalley, Simon Langer, Sergey Ryazanov, Andrei Leonov, Christian Griesinger, Felix Schmidt, Daniel Weckbecker, Kai Prager, Torsten Matthias, Armin Giese   +16 more
doaj   +1 more source

Physical therapy and deep brain stimulation in Parkinson’s Disease: Protocol for a pilot randomized controlled trial [PDF]

, 2018
Background Subthalamic nucleus deep brain stimulation (STN-DBS) reduces tremor, muscle stiffness, and bradykinesia in people with Parkinson’s Disease (PD).
Duncan, Ryan P, Earhart, Gammon M, Garbutt, Jane M, Perlmutter, Joel S, Van Dillen, Linda R   +4 more
core   +2 more sources

Risk factors for impulse control disorders and related behaviors in Parkinson’s disease: secondary analyses of the ICARUS study

Journal of Drug Assessment, 2019
Objective: Impulse control disorders and related behaviors (ICDs) are common in patients with Parkinson’s disease (PD), yet incidence and predictive factors are not fully understood.
P. Barone, A. Antonini, P. Stanzione, K. Annoni, M. Asgharnejad, U. Bonuccelli   +5 more
semanticscholar   +1 more source